Answers are grounded in this paper and cite their sources.
Chronic kidney disease (CKD) is a global problem of modern medicine. The neurological complications arising from this disease are an integral part of this condition because the kidneys and the brain have a similar anatomical structure of the vessels and a similar physiological structure of the processes occurring in them. Cognitive disorders (CD) that occur in CKD accompany almost every patient, regardless of the stage of the disease, and affect the psychological and social quality of life of patients. According to the literature, there are a number of substances called biomarkers, by determining which we can identify emerging neurological complications in the early stages of CKD. In our work, we used a new biomarker of renal function, cystatin C, which is characterized by free glomerular filtration and is not subject to tubular secretion. Its level in the blood serum of patients does not depend on the age, gender, muscle mass, ethnicity, diet, physical activity and bad habits of the patient.
No takes yet. Share an insight, caveat, or question.
Sevara Khudayarova (2022) studied this question.
Synapse has enriched 6 related papers. Consider them for comparative context: